Cooperative Agreement W58P052220014

This $1,000,000 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports research and development efforts by Akanocure Pharmaceuticals Inc. to optimize a novel, broad-spectrum antiviral and immunomodulatory agent for oral administration against coronaviruses. The project focuses on lead optimization, including the design, synthesis, and testing of analogs with improved drug-like properties for...

This Cooperative Agreement award of $996,606.00 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop stable prophylactic antibodies as long-term preventatives for infectious diseases such as influenza, malaria, tuberculosis, HIV, and the common cold. The project, awarded to Invvax, Inc., seeks to identify antibody mutations that significantly enhance stability, extending the lifespan of antibodies from weeks to years. This...

This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $995,600 to Purebiox, Inc. to develop an end-to-end solution for high-volume water microbiological testing. The project aims to enhance public health and safety by enabling early detection of waterborne viruses such as SARS-CoV-2 and norovirus, potentially weeks before outbreaks occur. The solution integrates a novel filtration cartridge and...

This Cooperative Agreement award, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a bioprocessing system to isolate and purify therapeutic antibodies directly from cell culture. The $999,998 award to Athem LLC, a minority-owned small business, will enable scaling up a novel nanoparticle-based purification media and an automated prototype system. The goal is to simplify the manufacturing of biologics, reduce...

This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Emerging Infections Programs (CFDA 93.317) provides $3,200,000 in funding over a 5-year period starting September 1, 2024 to establish a nationwide cohort of blood donors. The goal is to estimate the burden of respiratory viruses and characterize the immunologic response in this population. The primary awardee, Vitalant, will collaborate with sub-awardees Westat and the American Red Cross to...

This Cooperative Agreement awarded by the Uniformed Services University of the Health Sciences under the Uniformed Services University Medical Research Projects program (CFDA 12.750) provides $4,603,542.00 to assess domestic production of pharmaceutical products for the military health system. The award, effective November 7, 2024 through November 6, 2026, supports a collaboration between the prime awardee, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,994,888 Cooperative Agreement under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Research Triangle Institute (RTI International) to establish and maintain the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (REVAMPP) Coordinating and Data Sharing Center (CDSC). The CDSC will coordinate the REVAMPP network, comprised of 6-8 research centers, to...

This $255,966 National Science Foundation Technology, Innovation, and Partnerships award to Nano-Product Engineering, LLC will support the development of an antiviral/antimicrobial micropowder for application to personal protective equipment and respiratory equipment surfaces. The award period is from September 15, 2022 through May 31, 2023. The project aims to improve the protective properties of commonly used PPE and respiratory equipment, which typically only provides passive protection and...

This federal Cooperative Agreement award, valued at $6,915,297.00, was granted by the Defense Advanced Research Projects Agency (DARPA) under the Research and Technology Development program (CFDA 12.910). The award supports the "Assured Microbial Preservation in Harsh or Remote Areas (AMPHORA)" program, which aims to develop fundamental technologies for assured microbial preservation in challenging environments. Key products and services to be delivered under this award include:...

The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA) Biodefense Medical Countermeasure Development program (CFDA 93.360), has awarded a $61,822,336.47 cooperative agreement to Endo USA, Inc. The award, effective September 12, 2024 through November 30, 2035, supports the development of medical countermeasures such as vaccines, therapeutics, diagnostics, and devices to address biological, chemical, radiological, and nuclear...